Belite Bio, Inc
NASDAQ:BLTEBiotechnology
Healthcare
$151.02 +0.31%
+$0.46 today
- Market cap
- $6.08B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
52W Low $56.10High $200.00
Volume 0.14M
Average 0.17M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$36.99M
FY 2025 · Annual
Investing Cash Flow
-$305.11M
FY 2025 · Annual
Financing Cash Flow
$663.23M
FY 2025 · Annual
+693.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| Deferred Income Tax | 0 | (1.91M) | (4.69M) | 0 | 0 |
| Stock-Based Compensation | 1.53M | 1.48M | 3.82M | 8.99M | 38.92M |
| Change in Working Capital | 640K | (491K) | (2.43M) | 1.13M | 2.55M |
| Accounts Receivables | 0 | (32K) | (72K) | 74K | (66K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 640K | (459K) | (2.36M) | 1.06M | 2.62M |
| Other Non-Cash Items | (8K) | 1.91M | 4.69M | (3.66M) | (1.31M) |
| Operating Cash Flow | (7.47M) | (11.46M) | (29.84M) | (29.23M) | (36.99M) |
| Capital Expenditures | (74K) | (394K) | (63K) | (151K) | (178K) |
| Acquisitions (Net) | 18K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (188.27M) | (451.99M) |
| Sales of Investments | 0 | 0 | 0 | 77.84M | 147.07M |
| Other Investing Activities | 0 | 0 | 0 | (35K) | 0 |
| Investing Cash Flow | (56K) | (394K) | (63K) | (110.57M) | (305.11M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (583K) | 37.99M | 77.19M | 42.24M | 292.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.03M) | (1.23M) | 41.36M | 370.37M |
| Financing Cash Flow | (583K) | 36.96M | 75.96M | 83.6M | 663.23M |
| Effect of Forex Changes | (161K) | (366K) | 9K | (269K) | 117K |
| Net Change in Cash | (8.27M) | 24.75M | 46.07M | (56.48M) | 321.26M |
| Free Cash Flow | (7.55M) | (11.85M) | (29.9M) | (29.39M) | (37.17M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$77.6M
+ D&A$464.0K
+ Stock-Based Comp$38.9M
+ Deferred Tax$0
+ Working Capital$2.6M
- Other Non-Cash-$1.3M
= Operating Cash Flow-$37.0M
- Capex-$178.0K
= Free Cash Flow-$37.2M
Analysis
FY2025 free cash flow is -$37.2M. FCF conversion is 47.9% of net income. Operating cash flow was -$37.0M, with capex of -$178.0K. The largest bridge item is Stock-Based Comp at $38.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 6-K | 6-K filing | Oct 19, 2026 |
Does BLTE generate free cash flow?
Belite Bio, Inc (BLTE) generated -$37.17M of free cash flow in fiscal 2025.
How much operating cash flow does BLTE produce?
Operating cash flow was -$36.99M, before capital expenditures of $178,000.00.
Continue the stock analysis
Jump to another research area for this company.